Wize Pharma‘s LO2A eye drops result in clinically meaningful improvements in dry eye signs and symptoms in people with Sjögren’s syndrome, topline results from an exploratory Phase 4 trial show. The treatment continued to demonstrate a good safety profile, and was found to be at least as…

A Phase 4 clinical trial investigating LO2A eye drops, by Wize Pharma, as a treatment for dry eye symptoms in Sjögren’s syndrome patients is fully enrolled, the company announced. Topline results from the study, taking place at multiple sites in Israel, are expected by August. They will be used to…

Cyclosporine A treatment improves vision and increases tear production in people with moderate-to-severe dry eye disease, including those with Sjögren’s syndrome, an Egyptian study shows. The research, “Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease,” was published in…

LO2A eye drops significantly improve dry eye symptoms in Sjögren’s syndrome patients, according to a small Phase 2 clinical study performed in Hungary. The findings were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, on May 2 in Honolulu, Hawaii, in the poster presentation “…

Sjogren’s syndrome patients with chronic dry eyes have higher medical costs than people with dry eyes who don’t have Sjogren’s, a study from Eastern China shows. The research also points to a link between anxiety and medical costs for dry eye treatment in Sjogren’s patients. The study, “…

The protocol of a Phase 4 trial testing Wize Pharma‘s LO2A eye drops for the treatment of dry eye symptoms in Sjogren’s syndrome patients has received regulatory approval. Clearance from the Institutional Review Board (IRB) means the study is now allowed to start. The double-blind trial (NCT03319420), to be…